# Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring

> **NCT00642642** · PHASE2,PHASE3 · COMPLETED · sponsor: **Castle Creek Biosciences, LLC.** · enrollment: 122 (actual)

## Conditions studied

- Acne Scarring of the Face

## Interventions

- **BIOLOGICAL:** Autologous Human Fibroblasts (azficel-T)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00642642
- **Lead sponsor:** Castle Creek Biosciences, LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2013-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00642642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00642642, "Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00642642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*